The Senate report also urged CMS to address the "unintended consequences" of current reimbursement policies that don't cover oral anti-cancer therapies under Medicare Part B. Medicare only covers cancer drugs that a physician administers, which bars access to some potent therapies.
But cancer providers and oncology societies express puzzlement about this language in the Senate report, because the Medicare Part D prescription drug program that takes effect next year will cover oral medications.